What is the target blood pressure for patients with mild chronic kidney disease (eGFR 60–89 mL/min/1.73 m²)?

Target Blood Pressure for Mild CKD

For patients with mild CKD (eGFR 60-89 mL/min/1.73 m²), target a systolic blood pressure <120 mmHg using standardized office blood pressure measurement. 1

Rationale for This Target

The 2021 KDIGO guideline applies this <120 mmHg systolic target to all adult CKD patients not on dialysis, regardless of CKD stage, including mild CKD. 1 This recommendation is driven primarily by:

• Cardiovascular and mortality benefits: The lower target reduces cardiovascular events and all-cause mortality, which are the predominant risks in CKD patients (greater than kidney failure risk itself). 1
• Evidence base: The SPRINT trial, which included substantial numbers of CKD patients and older adults, forms the primary evidence supporting this target. 1
• Limited renoprotective evidence: There is minimal evidence that targeting <120 mmHg specifically protects kidney function, though some data suggest benefit in patients with proteinuria on long-term follow-up. 1

Critical Measurement Requirement

This <120 mmHg target applies ONLY to standardized office blood pressure measurement, not routine office BP. 1

• Standardized measurement involves automated readings after 5 minutes of quiet rest, without a healthcare provider present. 1
• Routine office BP measurements run 5-10 mmHg higher than standardized measurements, creating substantial risk of overtreatment if the <120 mmHg target is applied to routine measurements. 1
• The KDIGO guideline makes a strong (1B) recommendation for standardized BP measurement specifically to prevent this overtreatment risk. 1

Comparison to Other Guidelines

There is significant controversy and divergence among guidelines:

• 2021 KDIGO: <120 mmHg systolic (with standardized measurement) 1
• 2017 ACC/AHA: <130/80 mmHg 2
• 2023 European Society of Hypertension: 130-140 mmHg systolic, with recommendation against targeting <120/70 mmHg in all CKD patients 3
• 2012 KDIGO (previous): 130/80 mmHg with albuminuria or 140/90 mmHg without albuminuria 2

The European guidelines explicitly recommend against the aggressive <120 mmHg target, preferring 130-140 mmHg systolic. 3 This reflects ongoing uncertainty about the risk-benefit balance, particularly regarding renal adverse events. 4

Evidence Quality and Limitations

• A 2025 meta-analysis of 9 RCTs found that intensive BP control (<130/80 mmHg) showed a trend toward reduced all-cause mortality (RR 0.81, p=0.051) and cardiovascular events (RR 0.89, p=0.13), but these did not reach statistical significance. 5
• The same meta-analysis found no increase in serious renal events (50% eGFR reduction or ESKD) with intensive control. 5
• The KDIGO guideline acknowledges the evidence is weaker in certain subgroups where mild CKD patients often fall: those with diabetes, very low diastolic BP, white coat hypertension, and extremes of age. 1

Practical Implementation for Mild CKD

For a patient with mild CKD (eGFR 60-89):

1. Measure BP using standardized technique (automated, 5 minutes rest, no provider present). 1

2. If standardized BP ≥120 mmHg systolic: Initiate or intensify antihypertensive therapy targeting <120 mmHg. 1

3. First-line agents: Use ACE inhibitors or ARBs, particularly if any albuminuria is present (even <30 mg/g). 1, 6

4. Monitor for adverse effects: Watch for symptomatic hypotension, acute kidney injury, electrolyte abnormalities, particularly in patients with diabetes, low baseline diastolic BP, or advanced age. 1

5. If standardized measurement unavailable: Consider the more conservative European target of 130-140 mmHg systolic using routine office BP, as applying <120 mmHg to routine measurements risks overtreatment. 1, 3

Key Caveats

• The <120 mmHg target is conditional (not strong), meaning shared decision-making is essential, weighing individual cardiovascular risk against treatment burden and adverse effects. 1, 4
• Mild CKD patients often have comorbidities (diabetes, older age) where evidence for aggressive targets is less robust. 1
• Population-level data show only 69.5% of US CKD patients meet criteria for BP lowering under 2021 KDIGO versus 49.8% under 2012 KDIGO, representing substantial treatment intensification. 2